Wedbush Reiterates Outperform on Alpine Immune Sciences, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a $26 price target on the stock.

November 15, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reaffirmed an Outperform rating on Alpine Immune Sciences with a $26 price target, indicating a positive outlook for the stock.
The reiteration of an Outperform rating by a reputable analyst such as Robert Driscoll from Wedbush is a strong positive signal for investors, suggesting that the analyst has a bullish outlook on the stock's future performance. The maintained price target of $26 implies a significant upside potential from the current trading price, which could influence investor sentiment and lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100